JP2012510998A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012510998A5 JP2012510998A5 JP2011539525A JP2011539525A JP2012510998A5 JP 2012510998 A5 JP2012510998 A5 JP 2012510998A5 JP 2011539525 A JP2011539525 A JP 2011539525A JP 2011539525 A JP2011539525 A JP 2011539525A JP 2012510998 A5 JP2012510998 A5 JP 2012510998A5
- Authority
- JP
- Japan
- Prior art keywords
- imidazo
- pyrazin
- indazol
- pyridin
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 2-methoxy-pyridin-5-yl Chemical group 0.000 claims description 136
- 150000005829 chemical entities Chemical class 0.000 claims description 42
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 28
- 230000000694 effects Effects 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 18
- 201000010099 disease Diseases 0.000 claims description 17
- 229910052739 hydrogen Inorganic materials 0.000 claims description 17
- 239000001257 hydrogen Substances 0.000 claims description 17
- 230000005764 inhibitory process Effects 0.000 claims description 17
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 9
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 8
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 8
- 125000001072 heteroaryl group Chemical group 0.000 claims description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 8
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims description 6
- 125000004076 pyridyl group Chemical group 0.000 claims description 6
- LDLAEUFQUOXALI-UHFFFAOYSA-N 3-methylazetidin-3-ol Chemical compound CC1(O)CNC1 LDLAEUFQUOXALI-UHFFFAOYSA-N 0.000 claims description 4
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 claims description 4
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 4
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 4
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims description 4
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 4
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 4
- 230000007062 hydrolysis Effects 0.000 claims description 4
- 238000006460 hydrolysis reaction Methods 0.000 claims description 4
- 125000002883 imidazolyl group Chemical group 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims description 3
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims description 3
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims description 3
- LJGHYPLBDBRCRZ-UHFFFAOYSA-N 3-(3-aminophenyl)sulfonylaniline Chemical group NC1=CC=CC(S(=O)(=O)C=2C=C(N)C=CC=2)=C1 LJGHYPLBDBRCRZ-UHFFFAOYSA-N 0.000 claims description 3
- 125000003118 aryl group Chemical group 0.000 claims description 3
- 125000004429 atom Chemical group 0.000 claims description 3
- 125000004531 indol-5-yl group Chemical group [H]N1C([H])=C([H])C2=C([H])C(*)=C([H])C([H])=C12 0.000 claims description 3
- 125000006413 ring segment Chemical group 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 125000003107 substituted aryl group Chemical group 0.000 claims description 3
- WBMQTECYFWQKRK-XMMPIXPASA-N (3r)-1-[5-[[6-(1h-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino]pyridin-2-yl]-3-methylpiperidin-3-ol Chemical compound C1[C@](C)(O)CCCN1C(N=C1)=CC=C1NC1=NC(C=2C=C3NN=CC3=CC=2)=CN2C1=NC=C2 WBMQTECYFWQKRK-XMMPIXPASA-N 0.000 claims description 2
- WBMQTECYFWQKRK-DEOSSOPVSA-N (3s)-1-[5-[[6-(1h-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino]pyridin-2-yl]-3-methylpiperidin-3-ol Chemical compound C1[C@@](C)(O)CCCN1C(N=C1)=CC=C1NC1=NC(C=2C=C3NN=CC3=CC=2)=CN2C1=NC=C2 WBMQTECYFWQKRK-DEOSSOPVSA-N 0.000 claims description 2
- CVWASLZLFGDNNU-UHFFFAOYSA-N 1-[5-[[6-(1h-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino]pyridin-2-yl]-3-methylazetidin-3-ol Chemical compound C1C(C)(O)CN1C(N=C1)=CC=C1NC1=NC(C=2C=C3NN=CC3=CC=2)=CN2C1=NC=C2 CVWASLZLFGDNNU-UHFFFAOYSA-N 0.000 claims description 2
- WBMQTECYFWQKRK-UHFFFAOYSA-N 1-[5-[[6-(1h-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino]pyridin-2-yl]-3-methylpiperidin-3-ol Chemical compound C1C(C)(O)CCCN1C(N=C1)=CC=C1NC1=NC(C=2C=C3NN=CC3=CC=2)=CN2C1=NC=C2 WBMQTECYFWQKRK-UHFFFAOYSA-N 0.000 claims description 2
- MUXSPIYQJHBCNC-UHFFFAOYSA-N 1-[5-[[6-(1h-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino]pyridin-2-yl]azetidin-3-ol Chemical compound C1C(O)CN1C(N=C1)=CC=C1NC1=NC(C=2C=C3NN=CC3=CC=2)=CN2C1=NC=C2 MUXSPIYQJHBCNC-UHFFFAOYSA-N 0.000 claims description 2
- QLQHBDAWKYKMBQ-UHFFFAOYSA-N 1-[5-[[6-(1h-indol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino]pyridin-2-yl]-3-methylazetidin-3-ol Chemical compound C1C(C)(O)CN1C(N=C1)=CC=C1NC1=NC(C=2C=C3NC=CC3=CC=2)=CN2C1=NC=C2 QLQHBDAWKYKMBQ-UHFFFAOYSA-N 0.000 claims description 2
- GVTLJQGQDUOMGD-UHFFFAOYSA-N 1-[5-[[6-(1h-indol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino]pyridin-2-yl]-4-methylpiperidin-4-ol Chemical compound C1CC(C)(O)CCN1C(N=C1)=CC=C1NC1=NC(C=2C=C3NC=CC3=CC=2)=CN2C1=NC=C2 GVTLJQGQDUOMGD-UHFFFAOYSA-N 0.000 claims description 2
- AQWARLFPYXVRKX-UHFFFAOYSA-N 1-[5-[[6-(3,4-dihydro-2h-1,4-benzoxazin-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino]pyridin-2-yl]-4-methylpiperidin-4-ol Chemical compound C1CC(C)(O)CCN1C(N=C1)=CC=C1NC1=NC(C=2C=C3NCCOC3=CC=2)=CN2C1=NC=C2 AQWARLFPYXVRKX-UHFFFAOYSA-N 0.000 claims description 2
- SLQZHBCBHXYHRO-UHFFFAOYSA-N 1-[5-[[6-(3,4-dihydro-2h-1,4-benzoxazin-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino]pyridin-2-yl]azetidin-3-ol Chemical compound C1C(O)CN1C(N=C1)=CC=C1NC1=NC(C=2C=C3NCCOC3=CC=2)=CN2C1=NC=C2 SLQZHBCBHXYHRO-UHFFFAOYSA-N 0.000 claims description 2
- AMKMRSDGPQZQLS-UHFFFAOYSA-N 1-[6-[[6-(1h-indazol-6-yl)imidazo[1,2-a]pyridin-8-yl]amino]pyridin-3-yl]-3-methylazetidin-3-ol Chemical compound C1C(C)(O)CN1C(C=N1)=CC=C1NC1=CC(C=2C=C3NN=CC3=CC=2)=CN2C1=NC=C2 AMKMRSDGPQZQLS-UHFFFAOYSA-N 0.000 claims description 2
- MODZHSLQBONCHV-UHFFFAOYSA-N 1-[6-[[6-(1h-indazol-6-yl)imidazo[1,2-a]pyridin-8-yl]amino]pyridin-3-yl]azetidin-3-ol Chemical compound C1C(O)CN1C(C=N1)=CC=C1NC1=CC(C=2C=C3NN=CC3=CC=2)=CN2C1=NC=C2 MODZHSLQBONCHV-UHFFFAOYSA-N 0.000 claims description 2
- ORNSLMJWQDGQFF-UHFFFAOYSA-N 1h-pyrido[2,3-b][1,4]oxazin-2-one Chemical compound C1=CC=C2NC(=O)COC2=N1 ORNSLMJWQDGQFF-UHFFFAOYSA-N 0.000 claims description 2
- FDBCUIMAOSMMPA-UHFFFAOYSA-N 2-[4-[[6-(1h-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino]pyrazol-1-yl]ethanol Chemical compound C1=NN(CCO)C=C1NC1=NC(C=2C=C3NN=CC3=CC=2)=CN2C1=NC=C2 FDBCUIMAOSMMPA-UHFFFAOYSA-N 0.000 claims description 2
- IRXYTEKDDIDLNG-UHFFFAOYSA-N 2-[4-[[6-(1h-pyrrolo[3,2-b]pyridin-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino]pyrazol-1-yl]ethanol Chemical compound C1=NN(CCO)C=C1NC1=NC(C=2C=C3NC=CC3=NC=2)=CN2C1=NC=C2 IRXYTEKDDIDLNG-UHFFFAOYSA-N 0.000 claims description 2
- BZNKZCSPQJAFGH-UHFFFAOYSA-N 2-[4-[[6-(3,4-dihydro-2h-1,4-benzoxazin-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino]pyrazol-1-yl]ethanol Chemical compound C1=NN(CCO)C=C1NC1=NC(C=2C=C3NCCOC3=CC=2)=CN2C1=NC=C2 BZNKZCSPQJAFGH-UHFFFAOYSA-N 0.000 claims description 2
- SIUAQPJXONHYIN-UHFFFAOYSA-N 2-[4-[[6-(3,4-dihydro-2h-1,4-benzoxazin-7-yl)imidazo[1,2-a]pyrazin-8-yl]amino]pyrazol-1-yl]ethanol Chemical compound C1=NN(CCO)C=C1NC1=NC(C=2C=C3OCCNC3=CC=2)=CN2C1=NC=C2 SIUAQPJXONHYIN-UHFFFAOYSA-N 0.000 claims description 2
- SIVKFVXGDZLLQV-UHFFFAOYSA-N 2-[5-[[6-(1h-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino]pyridin-2-yl]-2-methylpropan-1-ol Chemical compound C1=NC(C(C)(CO)C)=CC=C1NC1=NC(C=2C=C3NN=CC3=CC=2)=CN2C1=NC=C2 SIVKFVXGDZLLQV-UHFFFAOYSA-N 0.000 claims description 2
- KRVYWBSYHNTNST-UHFFFAOYSA-N 2-[5-[[6-(1h-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino]pyridin-2-yl]oxyethanol Chemical compound C1=NC(OCCO)=CC=C1NC1=NC(C=2C=C3NN=CC3=CC=2)=CN2C1=NC=C2 KRVYWBSYHNTNST-UHFFFAOYSA-N 0.000 claims description 2
- GVZHUWSLJZJBOW-UHFFFAOYSA-N 2-n-[6-(1h-indazol-6-yl)imidazo[1,2-a]pyridin-8-yl]-5-n-(2-methoxyethyl)-5-n-methylpyridine-2,5-diamine Chemical compound N1=CC(N(C)CCOC)=CC=C1NC1=CC(C=2C=C3NN=CC3=CC=2)=CN2C1=NC=C2 GVZHUWSLJZJBOW-UHFFFAOYSA-N 0.000 claims description 2
- KEZHRKOVLKUYCQ-UHFFFAOYSA-N 3,3-dimethyl-1h-indol-2-one Chemical compound C1=CC=C2C(C)(C)C(=O)NC2=C1 KEZHRKOVLKUYCQ-UHFFFAOYSA-N 0.000 claims description 2
- ZZEQEKFGMMZTKM-UHFFFAOYSA-N 3,3-dimethyl-6-[8-[(6-morpholin-4-ylpyridin-3-yl)amino]imidazo[1,2-a]pyrazin-6-yl]-1h-indol-2-one Chemical compound C=1C=C2C(C)(C)C(=O)NC2=CC=1C(N=1)=CN2C=CN=C2C=1NC(C=N1)=CC=C1N1CCOCC1 ZZEQEKFGMMZTKM-UHFFFAOYSA-N 0.000 claims description 2
- RVWUJQUKULSUKG-UHFFFAOYSA-N 3-[4-[[6-(1h-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino]pyrazol-1-yl]propan-1-ol Chemical compound C1=NN(CCCO)C=C1NC1=NC(C=2C=C3NN=CC3=CC=2)=CN2C1=NC=C2 RVWUJQUKULSUKG-UHFFFAOYSA-N 0.000 claims description 2
- LLDKGUNKYFJNPV-UHFFFAOYSA-N 3-methylpiperidin-3-ol Chemical compound CC1(O)CCCNC1 LLDKGUNKYFJNPV-UHFFFAOYSA-N 0.000 claims description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- CXBLQEIODBBSQD-UHFFFAOYSA-N 4-methylpiperidin-4-ol Chemical compound CC1(O)CCNCC1 CXBLQEIODBBSQD-UHFFFAOYSA-N 0.000 claims description 2
- GFFAPGUIXUQLQE-UHFFFAOYSA-N 5-(1h-indol-6-yl)-n-(5-morpholin-4-ylpyridin-2-yl)pyrazolo[1,5-a]pyrimidin-7-amine Chemical compound C1COCCN1C(C=N1)=CC=C1NC1=CC(C=2C=C3NC=CC3=CC=2)=NC2=CC=NN12 GFFAPGUIXUQLQE-UHFFFAOYSA-N 0.000 claims description 2
- CGUPZIZXXGKGNQ-UHFFFAOYSA-N 5-(3,4-dihydro-2h-1,4-benzoxazin-6-yl)-n-(5-morpholin-4-ylpyridin-2-yl)pyrazolo[1,5-a]pyrimidin-7-amine Chemical compound C1=C2NCCOC2=CC=C1C(=NC1=CC=NN11)C=C1NC(N=C1)=CC=C1N1CCOCC1 CGUPZIZXXGKGNQ-UHFFFAOYSA-N 0.000 claims description 2
- UVNKRRHSMNYXBP-UHFFFAOYSA-N 5-(3-methylbenzimidazol-5-yl)-n-(5-morpholin-4-ylpyridin-2-yl)pyrazolo[1,5-a]pyrimidin-7-amine Chemical compound C1=C2N(C)C=NC2=CC=C1C(=NC1=CC=NN11)C=C1NC(N=C1)=CC=C1N1CCOCC1 UVNKRRHSMNYXBP-UHFFFAOYSA-N 0.000 claims description 2
- AFNKCFWWRHSLFW-UHFFFAOYSA-N 5-(3h-benzimidazol-5-yl)-n-(5-morpholin-4-ylpyridin-2-yl)pyrazolo[1,5-a]pyrimidin-7-amine Chemical compound C1COCCN1C(C=N1)=CC=C1NC1=CC(C=2C=C3NC=NC3=CC=2)=NC2=CC=NN12 AFNKCFWWRHSLFW-UHFFFAOYSA-N 0.000 claims description 2
- YYHKIHMXDFCULT-UHFFFAOYSA-N 5-[[6-(1h-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino]-1h-pyridin-2-one Chemical compound C1=NC(O)=CC=C1NC1=NC(C=2C=C3NN=CC3=CC=2)=CN2C1=NC=C2 YYHKIHMXDFCULT-UHFFFAOYSA-N 0.000 claims description 2
- 125000004539 5-benzimidazolyl group Chemical group N1=CNC2=C1C=CC(=C2)* 0.000 claims description 2
- MFNFCABYKPLVLW-UHFFFAOYSA-N 5-n-[6-(1h-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]-2-n-(2-methoxyethyl)-2-n-methylpyridine-2,5-diamine Chemical compound C1=NC(N(C)CCOC)=CC=C1NC1=NC(C=2C=C3NN=CC3=CC=2)=CN2C1=NC=C2 MFNFCABYKPLVLW-UHFFFAOYSA-N 0.000 claims description 2
- XFCQRUDDAVRMRJ-UHFFFAOYSA-N 6-(1-methylbenzimidazol-5-yl)-n-(6-morpholin-4-ylpyridin-3-yl)imidazo[1,2-a]pyrazin-8-amine Chemical compound C=1C=C2N(C)C=NC2=CC=1C(N=1)=CN2C=CN=C2C=1NC(C=N1)=CC=C1N1CCOCC1 XFCQRUDDAVRMRJ-UHFFFAOYSA-N 0.000 claims description 2
- MFSOZUSXQDDCNB-UHFFFAOYSA-N 6-(1h-indazol-6-yl)-n-(1-propan-2-ylpyrazol-4-yl)imidazo[1,2-a]pyrazin-8-amine Chemical compound C1=NN(C(C)C)C=C1NC1=NC(C=2C=C3NN=CC3=CC=2)=CN2C1=NC=C2 MFSOZUSXQDDCNB-UHFFFAOYSA-N 0.000 claims description 2
- OXAWWNWLWPJGSD-UHFFFAOYSA-N 6-(1h-indazol-6-yl)-n-(1h-indol-5-yl)imidazo[1,2-a]pyrazin-8-amine Chemical compound C1=C2C=NNC2=CC(C=2N=C(C3=NC=CN3C=2)NC=2C=C3C=CNC3=CC=2)=C1 OXAWWNWLWPJGSD-UHFFFAOYSA-N 0.000 claims description 2
- REGRKEPTFXYWPD-UHFFFAOYSA-N 6-(1h-indazol-6-yl)-n-(1h-indol-6-yl)imidazo[1,2-a]pyrazin-8-amine Chemical compound C1=C2C=NNC2=CC(C=2N=C(C3=NC=CN3C=2)NC=2C=C3NC=CC3=CC=2)=C1 REGRKEPTFXYWPD-UHFFFAOYSA-N 0.000 claims description 2
- LOZAVAJLPYYTML-UHFFFAOYSA-N 6-(1h-indazol-6-yl)-n-(2-methoxypyridin-4-yl)imidazo[1,2-a]pyrazin-8-amine Chemical compound C1=NC(OC)=CC(NC=2C3=NC=CN3C=C(N=2)C=2C=C3NN=CC3=CC=2)=C1 LOZAVAJLPYYTML-UHFFFAOYSA-N 0.000 claims description 2
- IOFMPQGEFPONCV-UHFFFAOYSA-N 6-(1h-indazol-6-yl)-n-(2-morpholin-4-ylpyrimidin-5-yl)imidazo[1,2-a]pyrazin-8-amine Chemical compound C1COCCN1C(N=C1)=NC=C1NC1=NC(C=2C=C3NN=CC3=CC=2)=CN2C1=NC=C2 IOFMPQGEFPONCV-UHFFFAOYSA-N 0.000 claims description 2
- QVALNOBDSBSJDA-UHFFFAOYSA-N 6-(1h-indazol-6-yl)-n-(3-methylbenzimidazol-5-yl)imidazo[1,2-a]pyrazin-8-amine Chemical compound C1=C2C=NNC2=CC(C=2N=C(C3=NC=CN3C=2)NC2=CC=C3N=CN(C3=C2)C)=C1 QVALNOBDSBSJDA-UHFFFAOYSA-N 0.000 claims description 2
- SMDZVMZCRFMZLC-UHFFFAOYSA-N 6-(1h-indazol-6-yl)-n-(6-morpholin-4-ylpyridazin-3-yl)imidazo[1,2-a]pyridin-8-amine Chemical compound C1COCCN1C(N=N1)=CC=C1NC1=CC(C=2C=C3NN=CC3=CC=2)=CN2C1=NC=C2 SMDZVMZCRFMZLC-UHFFFAOYSA-N 0.000 claims description 2
- BLAURGSMVPJHCW-UHFFFAOYSA-N 6-(1h-indazol-6-yl)-n-(6-morpholin-4-ylpyridin-3-yl)imidazo[1,2-a]pyrazin-8-amine Chemical compound C1COCCN1C(N=C1)=CC=C1NC1=NC(C=2C=C3NN=CC3=CC=2)=CN2C1=NC=C2 BLAURGSMVPJHCW-UHFFFAOYSA-N 0.000 claims description 2
- ILGMJEFGESPHHU-UHFFFAOYSA-N 6-(1h-indazol-6-yl)-n-[1-(2-methoxyethyl)pyrazol-4-yl]imidazo[1,2-a]pyrazin-8-amine Chemical compound C1=NN(CCOC)C=C1NC1=NC(C=2C=C3NN=CC3=CC=2)=CN2C1=NC=C2 ILGMJEFGESPHHU-UHFFFAOYSA-N 0.000 claims description 2
- YRFVCAQTEKISHD-UHFFFAOYSA-N 6-(1h-indazol-6-yl)-n-[6-(2-methoxyethoxy)pyridin-3-yl]imidazo[1,2-a]pyrazin-8-amine Chemical compound C1=NC(OCCOC)=CC=C1NC1=NC(C=2C=C3NN=CC3=CC=2)=CN2C1=NC=C2 YRFVCAQTEKISHD-UHFFFAOYSA-N 0.000 claims description 2
- LKPBCEATGKFYLL-UHFFFAOYSA-N 6-(1h-indol-6-yl)-n-(5-morpholin-4-ylpyridin-2-yl)imidazo[1,2-b]pyridazin-8-amine Chemical compound C1COCCN1C(C=N1)=CC=C1NC1=CC(C=2C=C3NC=CC3=CC=2)=NN2C1=NC=C2 LKPBCEATGKFYLL-UHFFFAOYSA-N 0.000 claims description 2
- ZZTPXLXGKRUVNP-UHFFFAOYSA-N 6-(1h-indol-6-yl)-n-(6-morpholin-4-ylpyridin-3-yl)imidazo[1,2-a]pyrazin-8-amine Chemical compound C1COCCN1C(N=C1)=CC=C1NC1=NC(C=2C=C3NC=CC3=CC=2)=CN2C1=NC=C2 ZZTPXLXGKRUVNP-UHFFFAOYSA-N 0.000 claims description 2
- JAIQINBVDXBDCL-UHFFFAOYSA-N 6-(2,3-dihydro-1h-indol-6-yl)-n-(2-methoxypyridin-4-yl)imidazo[1,2-a]pyrazin-8-amine Chemical compound C1=NC(OC)=CC(NC=2C3=NC=CN3C=C(N=2)C=2C=C3NCCC3=CC=2)=C1 JAIQINBVDXBDCL-UHFFFAOYSA-N 0.000 claims description 2
- JJJFPCRLZYYNSS-UHFFFAOYSA-N 6-(2,3-dimethylindazol-6-yl)-n-(6-morpholin-4-ylpyridin-3-yl)imidazo[1,2-a]pyrazin-8-amine Chemical compound C1=CC2=C(C)N(C)N=C2C=C1C(N=1)=CN2C=CN=C2C=1NC(C=N1)=CC=C1N1CCOCC1 JJJFPCRLZYYNSS-UHFFFAOYSA-N 0.000 claims description 2
- RJRRMFGLMTXVCJ-UHFFFAOYSA-N 6-(3,4-dihydro-2h-1,4-benzoxazin-6-yl)-n-(1h-indazol-6-yl)imidazo[1,2-a]pyrazin-8-amine Chemical compound C1=C2C=NNC2=CC(NC=2C3=NC=CN3C=C(N=2)C2=CC=C3OCCNC3=C2)=C1 RJRRMFGLMTXVCJ-UHFFFAOYSA-N 0.000 claims description 2
- UVVDMEJUOQLGNU-UHFFFAOYSA-N 6-(3,4-dihydro-2h-1,4-benzoxazin-6-yl)-n-(6-morpholin-4-ylpyridin-3-yl)imidazo[1,2-a]pyrazin-8-amine Chemical compound C1=C2NCCOC2=CC=C1C(N=1)=CN2C=CN=C2C=1NC(C=N1)=CC=C1N1CCOCC1 UVVDMEJUOQLGNU-UHFFFAOYSA-N 0.000 claims description 2
- HEDRGLFIFIZNRZ-UHFFFAOYSA-N 6-(3,4-dihydro-2h-1,4-benzoxazin-7-yl)-n-(6-morpholin-4-ylpyridin-3-yl)imidazo[1,2-a]pyrazin-8-amine Chemical compound C=1C=C2NCCOC2=CC=1C(N=1)=CN2C=CN=C2C=1NC(C=N1)=CC=C1N1CCOCC1 HEDRGLFIFIZNRZ-UHFFFAOYSA-N 0.000 claims description 2
- FJCFYHNLUHAOEQ-UHFFFAOYSA-N 6-(3-amino-1h-indazol-6-yl)-n-(5-morpholin-4-ylpyridin-2-yl)imidazo[1,2-b]pyridazin-8-amine Chemical compound C=1C=C2C(N)=NNC2=CC=1C(=NN1C=CN=C11)C=C1NC(N=C1)=CC=C1N1CCOCC1 FJCFYHNLUHAOEQ-UHFFFAOYSA-N 0.000 claims description 2
- NVNCYDLJZPDTJU-UHFFFAOYSA-N 6-(3-methylbenzimidazol-5-yl)-n-(6-morpholin-4-ylpyridin-3-yl)imidazo[1,2-a]pyrazin-8-amine Chemical compound C1=C2N(C)C=NC2=CC=C1C(N=1)=CN2C=CN=C2C=1NC(C=N1)=CC=C1N1CCOCC1 NVNCYDLJZPDTJU-UHFFFAOYSA-N 0.000 claims description 2
- XMIBZUXAYJDEPJ-UHFFFAOYSA-N 6-(3h-benzimidazol-5-yl)-n-(1h-indazol-6-yl)imidazo[1,2-a]pyrazin-8-amine Chemical compound C1=C2N=CNC2=CC(C=2N=C(C3=NC=CN3C=2)NC=2C=C3NN=CC3=CC=2)=C1 XMIBZUXAYJDEPJ-UHFFFAOYSA-N 0.000 claims description 2
- UBIGVLDELBKURT-UHFFFAOYSA-N 6-(3h-benzimidazol-5-yl)-n-(5-morpholin-4-ylpyridin-2-yl)imidazo[1,2-b]pyridazin-8-amine Chemical compound C1COCCN1C(C=N1)=CC=C1NC1=CC(C=2C=C3NC=NC3=CC=2)=NN2C1=NC=C2 UBIGVLDELBKURT-UHFFFAOYSA-N 0.000 claims description 2
- RSURYJHTBIMKJB-UHFFFAOYSA-N 6-(3h-benzimidazol-5-yl)-n-(6-morpholin-4-ylpyridin-3-yl)imidazo[1,2-a]pyrazin-8-amine Chemical compound C1COCCN1C(N=C1)=CC=C1NC1=NC(C=2C=C3NC=NC3=CC=2)=CN2C1=NC=C2 RSURYJHTBIMKJB-UHFFFAOYSA-N 0.000 claims description 2
- FFIRAJURARWRBR-UHFFFAOYSA-N 6-(4-fluoro-1h-indazol-6-yl)-n-(6-morpholin-4-ylpyridin-3-yl)imidazo[1,2-a]pyrazin-8-amine Chemical compound C=1C=2NN=CC=2C(F)=CC=1C(N=1)=CN2C=CN=C2C=1NC(C=N1)=CC=C1N1CCOCC1 FFIRAJURARWRBR-UHFFFAOYSA-N 0.000 claims description 2
- FXWKJRPKFLLYCP-UHFFFAOYSA-N 6-(5-fluoro-1h-indazol-6-yl)-n-(6-morpholin-4-ylpyridin-3-yl)imidazo[1,2-a]pyrazin-8-amine Chemical compound FC1=CC=2C=NNC=2C=C1C(N=1)=CN2C=CN=C2C=1NC(C=N1)=CC=C1N1CCOCC1 FXWKJRPKFLLYCP-UHFFFAOYSA-N 0.000 claims description 2
- YWWYKBLIOCGQPW-UHFFFAOYSA-N 6-[7-[(5-morpholin-4-ylpyridin-2-yl)amino]pyrazolo[1,5-a]pyrimidin-5-yl]-1,3-dihydroindol-2-one Chemical compound C1=C2NC(=O)CC2=CC=C1C(=NC1=CC=NN11)C=C1NC(N=C1)=CC=C1N1CCOCC1 YWWYKBLIOCGQPW-UHFFFAOYSA-N 0.000 claims description 2
- ULFQKRUDJIBCMJ-UHFFFAOYSA-N 6-[7-[(5-morpholin-4-ylpyridin-2-yl)amino]pyrazolo[1,5-a]pyrimidin-5-yl]-4h-1,4-benzoxazin-3-one Chemical compound C1=C2NC(=O)COC2=CC=C1C(=NC1=CC=NN11)C=C1NC(N=C1)=CC=C1N1CCOCC1 ULFQKRUDJIBCMJ-UHFFFAOYSA-N 0.000 claims description 2
- ACTDGIAISBVOBA-UHFFFAOYSA-N 6-[8-(3h-benzimidazol-5-ylamino)imidazo[1,2-a]pyrazin-6-yl]-4h-1,4-benzoxazin-3-one Chemical compound C1=C2NC=NC2=CC(NC=2C3=NC=CN3C=C(N=2)C2=CC=C3OCC(NC3=C2)=O)=C1 ACTDGIAISBVOBA-UHFFFAOYSA-N 0.000 claims description 2
- YJSOTIZELLALLH-UHFFFAOYSA-N 6-[8-[(2-methoxypyridin-4-yl)amino]imidazo[1,2-a]pyrazin-6-yl]-4h-1,4-benzoxazin-3-one Chemical compound C1=NC(OC)=CC(NC=2C3=NC=CN3C=C(N=2)C=2C=C3NC(=O)COC3=CC=2)=C1 YJSOTIZELLALLH-UHFFFAOYSA-N 0.000 claims description 2
- GVHAQVNWVMWREB-UHFFFAOYSA-N 6-[8-[(6-morpholin-4-ylpyridin-3-yl)amino]imidazo[1,2-a]pyrazin-6-yl]-1,3-dihydroindol-2-one Chemical compound C1=C2NC(=O)CC2=CC=C1C(N=1)=CN2C=CN=C2C=1NC(C=N1)=CC=C1N1CCOCC1 GVHAQVNWVMWREB-UHFFFAOYSA-N 0.000 claims description 2
- CPVHSKNQELNOSO-UHFFFAOYSA-N 6-[8-[(6-morpholin-4-ylpyridin-3-yl)amino]imidazo[1,2-a]pyrazin-6-yl]quinazolin-2-amine Chemical compound C1=CC2=NC(N)=NC=C2C=C1C(N=1)=CN2C=CN=C2C=1NC(C=N1)=CC=C1N1CCOCC1 CPVHSKNQELNOSO-UHFFFAOYSA-N 0.000 claims description 2
- BAAULUYTQPWZKP-UHFFFAOYSA-N 6-[8-[[6-[2-hydroxyethyl(methyl)amino]pyridin-3-yl]amino]imidazo[1,2-a]pyrazin-6-yl]-4h-1,4-benzoxazin-3-one Chemical compound C1=NC(N(CCO)C)=CC=C1NC1=NC(C=2C=C3NC(=O)COC3=CC=2)=CN2C1=NC=C2 BAAULUYTQPWZKP-UHFFFAOYSA-N 0.000 claims description 2
- QVJUPYNRFCSHDO-UHFFFAOYSA-N 7-[8-[(6-morpholin-4-ylpyridin-3-yl)amino]imidazo[1,2-a]pyrazin-6-yl]-1h-pyrido[2,3-b][1,4]oxazin-2-one Chemical compound C1=C2NC(=O)COC2=NC=C1C(N=1)=CN2C=CN=C2C=1NC(C=N1)=CC=C1N1CCOCC1 QVJUPYNRFCSHDO-UHFFFAOYSA-N 0.000 claims description 2
- KUQZQLWHXSMWCG-UHFFFAOYSA-N 7-[8-[[1-(2-hydroxyethyl)pyrazol-4-yl]amino]imidazo[1,2-a]pyrazin-6-yl]-1h-pyrido[2,3-b][1,4]oxazin-2-one Chemical compound C1=NN(CCO)C=C1NC1=NC(C=2C=C3NC(=O)COC3=NC=2)=CN2C1=NC=C2 KUQZQLWHXSMWCG-UHFFFAOYSA-N 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 208000004736 B-Cell Leukemia Diseases 0.000 claims description 2
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 206010020751 Hypersensitivity Diseases 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 2
- FTZDSFCLGHITMM-GOSISDBHSA-N [(2r)-4-[5-[[6-(1h-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino]pyridin-2-yl]morpholin-2-yl]methanol Chemical compound C1CO[C@@H](CO)CN1C(N=C1)=CC=C1NC1=NC(C=2C=C3NN=CC3=CC=2)=CN2C1=NC=C2 FTZDSFCLGHITMM-GOSISDBHSA-N 0.000 claims description 2
- FTZDSFCLGHITMM-SFHVURJKSA-N [(2s)-4-[5-[[6-(1h-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino]pyridin-2-yl]morpholin-2-yl]methanol Chemical compound C1CO[C@H](CO)CN1C(N=C1)=CC=C1NC1=NC(C=2C=C3NN=CC3=CC=2)=CN2C1=NC=C2 FTZDSFCLGHITMM-SFHVURJKSA-N 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 230000000172 allergic effect Effects 0.000 claims description 2
- 201000010105 allergic rhinitis Diseases 0.000 claims description 2
- 230000007815 allergy Effects 0.000 claims description 2
- 208000010668 atopic eczema Diseases 0.000 claims description 2
- GMWFCJXSQQHBPI-UHFFFAOYSA-N azetidin-3-ol Chemical compound OC1CNC1 GMWFCJXSQQHBPI-UHFFFAOYSA-N 0.000 claims description 2
- 125000004540 benzothiazol-5-yl group Chemical group S1C=NC2=C1C=CC(=C2)* 0.000 claims description 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 238000001514 detection method Methods 0.000 claims description 2
- 125000005434 dihydrobenzoxazinyl group Chemical group O1N(CCC2=C1C=CC=C2)* 0.000 claims description 2
- 125000001070 dihydroindolyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- TVXBXCYRWQVAHC-UHFFFAOYSA-N n,6-bis(1h-indazol-6-yl)imidazo[1,2-a]pyrazin-8-amine Chemical compound C1=C2C=NNC2=CC(C=2N=C(C3=NC=CN3C=2)NC=2C=C3NN=CC3=CC=2)=C1 TVXBXCYRWQVAHC-UHFFFAOYSA-N 0.000 claims description 2
- VDWUKUJNGKUJRK-UHFFFAOYSA-N n-(1-ethylpyrazol-4-yl)-6-(1h-indazol-6-yl)imidazo[1,2-a]pyrazin-8-amine Chemical compound C1=NN(CC)C=C1NC1=NC(C=2C=C3NN=CC3=CC=2)=CN2C1=NC=C2 VDWUKUJNGKUJRK-UHFFFAOYSA-N 0.000 claims description 2
- GMVKFRBATNDGIQ-UHFFFAOYSA-N n-(1-ethylpyrazol-4-yl)-6-(1h-pyrrolo[3,2-b]pyridin-6-yl)imidazo[1,2-a]pyrazin-8-amine Chemical compound C1=NN(CC)C=C1NC1=NC(C=2C=C3NC=CC3=NC=2)=CN2C1=NC=C2 GMVKFRBATNDGIQ-UHFFFAOYSA-N 0.000 claims description 2
- XVPSBTQBKHTHAA-UHFFFAOYSA-N n-(1h-indazol-5-yl)-6-(1-methylindazol-5-yl)imidazo[1,2-a]pyrazin-8-amine Chemical compound C1=C2NN=CC2=CC(NC=2C3=NC=CN3C=C(N=2)C=2C=C3C=NN(C3=CC=2)C)=C1 XVPSBTQBKHTHAA-UHFFFAOYSA-N 0.000 claims description 2
- VMFCOXUYVZFXMW-UHFFFAOYSA-N n-(1h-indazol-5-yl)-6-(1h-indazol-6-yl)imidazo[1,2-a]pyrazin-8-amine Chemical compound C1=C2C=NNC2=CC(C=2N=C(C3=NC=CN3C=2)NC=2C=C3C=NNC3=CC=2)=C1 VMFCOXUYVZFXMW-UHFFFAOYSA-N 0.000 claims description 2
- CHFMKCITFBGXOU-UHFFFAOYSA-N n-(3-methylbenzimidazol-5-yl)-6-(1-methylindazol-6-yl)imidazo[1,2-a]pyrazin-8-amine Chemical compound C1=C2C=NN(C)C2=CC(C=2N=C(C3=NC=CN3C=2)NC2=CC=C3N=CN(C3=C2)C)=C1 CHFMKCITFBGXOU-UHFFFAOYSA-N 0.000 claims description 2
- BNCKTNDSKXWEAE-UHFFFAOYSA-N n-(3h-benzimidazol-5-yl)-6-(1,3-benzoxazol-6-yl)imidazo[1,2-a]pyrazin-8-amine Chemical compound C1=C2N=COC2=CC(C=2N=C(C3=NC=CN3C=2)NC=2C=C3NC=NC3=CC=2)=C1 BNCKTNDSKXWEAE-UHFFFAOYSA-N 0.000 claims description 2
- QETBUDBNKCLIMS-UHFFFAOYSA-N n-(3h-benzimidazol-5-yl)-6-(1h-indazol-6-yl)imidazo[1,2-a]pyrazin-8-amine Chemical compound C1=C2C=NNC2=CC(C=2N=C(C3=NC=CN3C=2)NC=2C=C3NC=NC3=CC=2)=C1 QETBUDBNKCLIMS-UHFFFAOYSA-N 0.000 claims description 2
- MZUJQNZLHJMIAT-UHFFFAOYSA-N n-(5-cyclopropyl-1h-pyrazol-3-yl)-6-(1h-indazol-6-yl)imidazo[1,2-a]pyrazin-8-amine Chemical compound C1CC1C1=NNC(NC=2C3=NC=CN3C=C(N=2)C=2C=C3NN=CC3=CC=2)=C1 MZUJQNZLHJMIAT-UHFFFAOYSA-N 0.000 claims description 2
- JLEPQGXYORIGHS-UHFFFAOYSA-N n-[6-(1h-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]-1,3-benzothiazol-5-amine Chemical compound C1=C2C=NNC2=CC(C=2N=C(C3=NC=CN3C=2)NC=2C=C3N=CSC3=CC=2)=C1 JLEPQGXYORIGHS-UHFFFAOYSA-N 0.000 claims description 2
- ACIGLWSVXQNOCW-UHFFFAOYSA-N n-[6-(1h-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]-1,3-benzothiazol-6-amine Chemical compound C1=C2C=NNC2=CC(C=2N=C(C3=NC=CN3C=2)NC=2C=C3SC=NC3=CC=2)=C1 ACIGLWSVXQNOCW-UHFFFAOYSA-N 0.000 claims description 2
- XMGDBWUJMQDUNG-UHFFFAOYSA-N n-[6-(1h-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]-1,3-benzoxazol-5-amine Chemical compound C1=C2C=NNC2=CC(C=2N=C(C3=NC=CN3C=2)NC=2C=C3N=COC3=CC=2)=C1 XMGDBWUJMQDUNG-UHFFFAOYSA-N 0.000 claims description 2
- PFAYSSMPEZALNG-UHFFFAOYSA-N n-[6-(1h-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]-1,3-benzoxazol-6-amine Chemical compound C1=C2C=NNC2=CC(C=2N=C(C3=NC=CN3C=2)NC=2C=C3OC=NC3=CC=2)=C1 PFAYSSMPEZALNG-UHFFFAOYSA-N 0.000 claims description 2
- QWMVMARPBJZREH-UHFFFAOYSA-N n-[6-(3-aminoquinolin-6-yl)imidazo[1,2-a]pyrazin-8-yl]-1,3-benzothiazol-5-amine Chemical compound C1=C2SC=NC2=CC(NC=2C3=NC=CN3C=C(N=2)C=2C=CC3=NC=C(C=C3C=2)N)=C1 QWMVMARPBJZREH-UHFFFAOYSA-N 0.000 claims description 2
- GMHCQKIFMVOIIX-UHFFFAOYSA-N n-[6-[2-(dimethylamino)ethoxy]pyridin-3-yl]-6-(1h-indazol-6-yl)imidazo[1,2-a]pyrazin-8-amine Chemical compound C1=NC(OCCN(C)C)=CC=C1NC1=NC(C=2C=C3NN=CC3=CC=2)=CN2C1=NC=C2 GMHCQKIFMVOIIX-UHFFFAOYSA-N 0.000 claims description 2
- YMCMSVVYWKJYME-UHFFFAOYSA-N n-imidazo[1,2-a]pyridin-6-yl-6-(1h-indazol-6-yl)imidazo[1,2-a]pyrazin-8-amine Chemical compound C1=C2C=NNC2=CC(C=2N=C(C3=NC=CN3C=2)NC2=CN3C=CN=C3C=C2)=C1 YMCMSVVYWKJYME-UHFFFAOYSA-N 0.000 claims description 2
- 125000002971 oxazolyl group Chemical group 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 208000030761 polycystic kidney disease Diseases 0.000 claims description 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 125000000335 thiazolyl group Chemical group 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 13
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- SBWBNCVVYPXVJY-UHFFFAOYSA-N 2-[[5-[[6-(3,4-dihydro-2h-1,4-benzoxazin-7-yl)imidazo[1,2-a]pyrazin-8-yl]amino]pyridin-2-yl]-methylamino]ethanol Chemical compound C1=NC(N(CCO)C)=CC=C1NC1=NC(C=2C=C3OCCNC3=CC=2)=CN2C1=NC=C2 SBWBNCVVYPXVJY-UHFFFAOYSA-N 0.000 claims 1
- MSOZVQWIBDYXLI-UHFFFAOYSA-N 6-(1h-indazol-6-yl)-n-[6-(4-propan-2-ylpiperazin-1-yl)pyridin-3-yl]imidazo[1,2-a]pyrazin-8-amine Chemical class C1CN(C(C)C)CCN1C(N=C1)=CC=C1NC1=NC(C=2C=C3NN=CC3=CC=2)=CN2C1=NC=C2 MSOZVQWIBDYXLI-UHFFFAOYSA-N 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- XMUVBXMTSPNLPS-UHFFFAOYSA-N n-(1-ethyl-5-methylpyrazol-3-yl)-6-(1h-indazol-6-yl)imidazo[1,2-a]pyridin-8-amine Chemical compound C1=C(C)N(CC)N=C1NC1=CC(C=2C=C3NN=CC3=CC=2)=CN2C1=NC=C2 XMUVBXMTSPNLPS-UHFFFAOYSA-N 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 description 47
- 150000002431 hydrogen Chemical class 0.000 description 6
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- KBSDNGMTLHBUAW-UHFFFAOYSA-N 6-[8-[(6-morpholin-4-ylpyridin-3-yl)amino]imidazo[1,2-a]pyrazin-6-yl]-4h-1,4-benzoxazin-3-one Chemical compound C1=C2NC(=O)COC2=CC=C1C(N=1)=CN2C=CN=C2C=1NC(C=N1)=CC=C1N1CCOCC1 KBSDNGMTLHBUAW-UHFFFAOYSA-N 0.000 description 1
- NAYHWSHMAFTGBK-UHFFFAOYSA-N 6-[8-[[1-(2-hydroxyethyl)pyrazol-4-yl]amino]imidazo[1,2-a]pyrazin-6-yl]-4h-1,4-benzoxazin-3-one Chemical compound C1=NN(CCO)C=C1NC1=NC(C=2C=C3NC(=O)COC3=CC=2)=CN2C1=NC=C2 NAYHWSHMAFTGBK-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 230000010398 acute inflammatory response Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical compound C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12059008P | 2008-12-08 | 2008-12-08 | |
| US61/120,590 | 2008-12-08 | ||
| US14053508P | 2008-12-23 | 2008-12-23 | |
| US61/140,535 | 2008-12-23 | ||
| US24098309P | 2009-09-09 | 2009-09-09 | |
| US61/240,983 | 2009-09-09 | ||
| PCT/US2009/006446 WO2010068258A1 (en) | 2008-12-08 | 2009-12-07 | Imidazopyrazine syk inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014105805A Division JP2014148546A (ja) | 2008-12-08 | 2014-05-22 | イミダゾピラジンｓｙｋ阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012510998A JP2012510998A (ja) | 2012-05-17 |
| JP2012510998A5 true JP2012510998A5 (https=) | 2013-01-31 |
| JP5696052B2 JP5696052B2 (ja) | 2015-04-08 |
Family
ID=42241250
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011539525A Expired - Fee Related JP5696052B2 (ja) | 2008-12-08 | 2009-12-07 | イミダゾピラジンｓｙｋ阻害剤 |
| JP2014105805A Withdrawn JP2014148546A (ja) | 2008-12-08 | 2014-05-22 | イミダゾピラジンｓｙｋ阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014105805A Withdrawn JP2014148546A (ja) | 2008-12-08 | 2014-05-22 | イミダゾピラジンｓｙｋ阻害剤 |
Country Status (18)
| Country | Link |
|---|---|
| US (5) | US8440667B2 (https=) |
| EP (2) | EP2373318B1 (https=) |
| JP (2) | JP5696052B2 (https=) |
| KR (1) | KR101743784B1 (https=) |
| CN (2) | CN104059073B (https=) |
| AU (2) | AU2009325133B2 (https=) |
| BR (1) | BRPI0922226A2 (https=) |
| CA (1) | CA2745871C (https=) |
| CL (1) | CL2011001361A1 (https=) |
| CO (1) | CO6390109A2 (https=) |
| EA (1) | EA021293B1 (https=) |
| ES (1) | ES2744541T3 (https=) |
| IL (2) | IL213405A0 (https=) |
| MX (1) | MX2011006094A (https=) |
| NZ (1) | NZ593460A (https=) |
| PE (1) | PE20120121A1 (https=) |
| SG (2) | SG171993A1 (https=) |
| WO (1) | WO2010068258A1 (https=) |
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5496915B2 (ja) | 2008-02-13 | 2014-05-21 | シージーアイ ファーマシューティカルズ，インコーポレーテッド | ６−アリール−イミダゾ［１，２−ａ］ピラジン誘導体、その製造方法、及びその使用方法 |
| CN102307474B (zh) | 2008-12-08 | 2015-04-01 | 吉利德康涅狄格股份有限公司 | 咪唑并吡嗪syk抑制剂 |
| EA021293B1 (ru) | 2008-12-08 | 2015-05-29 | Джилид Коннектикут, Инк. | ИМИДАЗОПИРАЗИНОВЫЕ ИНГИБИТОРЫ Syk, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ИМИДАЗОПИРАЗИНОВЫЕ ИНГИБИТОРЫ Syk, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| US8450321B2 (en) | 2008-12-08 | 2013-05-28 | Gilead Connecticut, Inc. | 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor |
| WO2011056895A1 (en) * | 2009-11-03 | 2011-05-12 | University Of Notre Dame Du Lac | Ionic liquids comprising heteraromatic anions |
| SG181857A1 (en) | 2009-12-23 | 2012-07-30 | Takeda Pharmaceutical | Fused heteroaromatic pyrrolidinones as syk inhibitors |
| CA2789276A1 (en) * | 2010-02-09 | 2011-08-18 | Drexel University | New signaling molecule involved in ultraviolet damage to skin |
| CN103168039B (zh) | 2010-03-11 | 2016-08-03 | 吉利德康涅狄格公司 | 咪唑并吡啶类syk抑制剂 |
| MX363696B (es) | 2011-04-21 | 2019-03-28 | Origenis Gmbh | Pirazolo[4,3-d]pirimidinas utiles como inhibidores de cinasas. |
| EP2707357B1 (en) | 2011-05-10 | 2017-01-18 | Merck Sharp & Dohme Corp. | Pyridyl aminopyridines as syk inhibitors |
| US9145391B2 (en) | 2011-05-10 | 2015-09-29 | Merck Sharp & Dohme Corp. | Bipyridylaminopyridines as Syk inhibitors |
| JP6026525B2 (ja) | 2011-06-22 | 2016-11-16 | 武田薬品工業株式会社 | 置換６−アザ−イソインドリン−１−オン誘導体 |
| WO2013052393A1 (en) | 2011-10-05 | 2013-04-11 | Merck Sharp & Dohme Corp. | 3-PYRIDYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (Syk) INHIBITORS |
| WO2013052391A1 (en) | 2011-10-05 | 2013-04-11 | Merck Sharp & Dohme Corp. | PHENYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (Syk) INHIBITORS |
| EP2763976B1 (en) | 2011-10-05 | 2016-05-18 | Merck Sharp & Dohme Corp. | 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors |
| RU2662443C2 (ru) * | 2011-11-01 | 2018-07-26 | Ф. Хоффманн-Ля Рош Аг | Имидазопиридазины |
| DK2788349T3 (en) | 2011-12-09 | 2017-01-30 | Chiesi Farm Spa | kinase inhibitors |
| KR20140105459A (ko) | 2011-12-09 | 2014-09-01 | 키에시 파르마슈티시 엣스. 피. 에이. | 키나아제 억제제 |
| WO2013104573A1 (en) | 2012-01-10 | 2013-07-18 | F. Hoffmann-La Roche Ag | Pyridazine amide compounds and their use as syk inhibitors |
| WO2013188856A1 (en) * | 2012-06-14 | 2013-12-19 | Gilead Connecticut, Inc. | Imidazopyrazine syk inhibitors |
| US9487504B2 (en) | 2012-06-20 | 2016-11-08 | Merck Sharp & Dohme Corp. | Imidazolyl analogs as syk inhibitors |
| EP2863914B1 (en) | 2012-06-20 | 2018-10-03 | Merck Sharp & Dohme Corp. | Pyrazolyl derivatives as syk inhibitors |
| EP2863915B1 (en) | 2012-06-22 | 2017-12-06 | Merck Sharp & Dohme Corp. | SUBSTITUTED DIAZINE AND TRIAZINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS |
| EP2863916B1 (en) | 2012-06-22 | 2018-07-18 | Merck Sharp & Dohme Corp. | Substituted pyridine spleen tyrosine kinase (syk) inhibitors |
| EP2884982B1 (en) | 2012-08-20 | 2017-09-20 | Merck Sharp & Dohme Corp. | SUBSTITUTED PHENYL SPLEEN TYROSINE KINASE (Syk) INHIBITORS |
| HK1213181A1 (zh) | 2012-09-27 | 2016-06-30 | Portola Pharmaceuticals, Inc. | 雙環氧雜內酰胺激酶抑制劑 |
| EP2900665B1 (en) | 2012-09-28 | 2018-01-03 | Merck Sharp & Dohme Corp. | Triazolyl derivatives as syk inhibitors |
| WO2014060112A1 (en) * | 2012-10-19 | 2014-04-24 | Origenis Gmbh | Pyrazolo[4,3-d]pyrimidines as kinase inhibitors |
| EP2914296B2 (en) | 2012-11-01 | 2021-09-29 | Infinity Pharmaceuticals, Inc. | Treatment of cancers using pi3 kinase isoform modulators |
| WO2014093191A1 (en) | 2012-12-12 | 2014-06-19 | Merck Sharp & Dohme Corp. | AMINO-PYRIMIDINE-CONTAINING SPLEEN TYROSINE KINASE (Syk) INHIBITORS |
| EP2934525B1 (en) | 2012-12-21 | 2019-05-08 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminopyridines as spleen tyrosine kinase inhibitors |
| US20160024051A1 (en) | 2013-03-15 | 2016-01-28 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
| EP2988749B1 (en) | 2013-04-26 | 2019-08-14 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminopyrimidines as spleen tyrosine kinase inhibitors |
| EP2988744A4 (en) | 2013-04-26 | 2016-11-02 | Merck Sharp & Dohme | THIAZOLSUBSTITUTED AMINOHETEROARYLE AS MILZTYROSINKINASE INHIBITOR |
| SG11201509842SA (en) | 2013-05-30 | 2015-12-30 | Infinity Pharmaceuticals Inc | Treatment of cancers using pi3 kinase isoform modulators |
| RU2015151886A (ru) | 2013-06-06 | 2017-06-08 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Ингибиторы киназ |
| CA2919522C (en) | 2013-07-30 | 2019-02-26 | Gilead Connecticut, Inc. | Formulation of syk inhibitors |
| EA029281B1 (ru) | 2013-07-30 | 2018-03-30 | Джилид Коннектикут, Инк. | Полиморф ингибиторов syk |
| NZ715747A (en) | 2013-07-31 | 2017-03-31 | Gilead Sciences Inc | Syk inhibitors |
| WO2015048765A1 (en) | 2013-09-30 | 2015-04-02 | University Of Notre Dame Du Lac | Compounds, complexes, compositions, methods and systems for heating and cooling |
| MX2021012208A (es) | 2013-10-04 | 2023-01-19 | Infinity Pharmaceuticals Inc | Compuestos heterocíclicos y usos de los mismos. |
| WO2015051241A1 (en) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| WO2015061204A1 (en) | 2013-10-21 | 2015-04-30 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| US10086331B2 (en) | 2013-11-05 | 2018-10-02 | University Of Notre Dame Du Lac | Carbon dioxide capture using phase change ionic liquids |
| CN105764516A (zh) | 2013-12-04 | 2016-07-13 | 吉利德科学公司 | 治疗癌症的方法 |
| US9783531B2 (en) | 2013-12-20 | 2017-10-10 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors |
| EP3083560B1 (en) | 2013-12-20 | 2021-10-27 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors |
| US9822107B2 (en) | 2013-12-20 | 2017-11-21 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors |
| TWI662037B (zh) * | 2013-12-23 | 2019-06-11 | 美商基利科學股份有限公司 | 脾酪胺酸激酶抑制劑 |
| US9290505B2 (en) | 2013-12-23 | 2016-03-22 | Gilead Sciences, Inc. | Substituted imidazo[1,2-a]pyrazines as Syk inhibitors |
| WO2015138273A1 (en) | 2014-03-13 | 2015-09-17 | Merck Sharp & Dohme Corp. | 2-pyrazine carboxamides as spleen tyrosine kinase inhibitors |
| NZ724368A (en) | 2014-03-19 | 2023-07-28 | Infinity Pharmaceuticals Inc | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders |
| US20150320754A1 (en) | 2014-04-16 | 2015-11-12 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| WO2015157955A1 (en) * | 2014-04-17 | 2015-10-22 | Abbvie Inc. | Heterocyclic btk inhibit ors |
| BR112016028641A2 (pt) | 2014-07-14 | 2017-08-22 | Gilead Sciences Inc | ?método para tratar câncer? |
| TW201617074A (zh) | 2014-07-14 | 2016-05-16 | 吉李德科學股份有限公司 | Ｓｙｋ（脾酪胺酸激酶）抑制劑 |
| WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| CN107709336B (zh) * | 2015-06-12 | 2021-06-22 | 杭州英创医药科技有限公司 | 作为Syk抑制剂和/或Syk-HDAC双重抑制剂的杂环化合物 |
| ES2745284T3 (es) * | 2015-09-11 | 2020-02-28 | Boehringer Ingelheim Int | Heteroarilos sustituidos con pirazolilo y su uso como medicamentos |
| EP4585268A3 (en) | 2015-09-14 | 2025-10-15 | Twelve Therapeutics, Inc. | Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same |
| WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| RU2754507C2 (ru) | 2016-06-24 | 2021-09-02 | Инфинити Фармасьютикалз, Инк. | Комбинированная терапия |
| US10111882B2 (en) | 2016-09-14 | 2018-10-30 | Gilead Sciences, Inc. | SYK inhibitors |
| TW201822764A (zh) | 2016-09-14 | 2018-07-01 | 美商基利科學股份有限公司 | Syk抑制劑 |
| US11142535B2 (en) * | 2016-12-12 | 2021-10-12 | Hangzhou Innogate Pharma Co., Ltd. | Heterocyclic compound as Syk inhibitor and/or Syk-HDAC dual inhibitor |
| WO2018195471A1 (en) | 2017-04-21 | 2018-10-25 | Gilead Sciences, Inc. | Syk inhibitors in combination with hypomethylating agents |
| CA3073871A1 (en) | 2017-08-25 | 2019-02-28 | Gilead Sciences, Inc. | Polymorphs of syk inhibitors |
| AU2019245403B2 (en) * | 2018-03-29 | 2025-02-06 | Board Of Regents, The University Of Texas System | Imidazopiperazine inhibitors of transcription activating proteins |
| CN113950479A (zh) | 2019-02-22 | 2022-01-18 | 克洛诺斯生物股份有限公司 | 作为syk抑制剂的缩合吡嗪的固体形式 |
| US20220143049A1 (en) | 2019-03-21 | 2022-05-12 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| US12605387B2 (en) | 2020-07-24 | 2026-04-21 | Secura Bio, Inc. | Treatment of cancers using PI3 kinase isoform modulators |
| CN120239624A (zh) | 2022-11-23 | 2025-07-01 | 皇家飞利浦有限公司 | 控制触觉呼吸引导设备 |
Family Cites Families (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4337609A (en) | 1980-09-17 | 1982-07-06 | Pitney Bowes Inc. | Envelope stuffing apparatus |
| FR2607813B1 (fr) | 1986-12-05 | 1989-03-31 | Montpellier I Universite | Alkylamino-8 imidazo (1,2-a) pyrazines et derives, leur preparation et leur application en therapeutique |
| US5137876A (en) | 1990-10-12 | 1992-08-11 | Merck & Co., Inc. | Nucleoside antiviral and anti-inflammatory compounds and compositions and methods for using same |
| DE4327027A1 (de) * | 1993-02-15 | 1994-08-18 | Bayer Ag | Imidazoazine |
| DE4337611A1 (de) * | 1993-11-04 | 1995-05-11 | Boehringer Ingelheim Kg | Neue Benzoylguanidine, ihre Herstellung und ihre Verwendung in Arzneimitteln |
| DE4337656C2 (de) | 1993-11-04 | 1996-01-18 | Audi Ag | Insassenschutzvorrichtung für Kraftfahrzeuge |
| DE4337609A1 (de) | 1993-11-04 | 1995-05-11 | Boehringer Ingelheim Kg | Neue Pyrazincarboxamidderivate, ihre Herstellung und ihre Verwendung in Arzneimitteln |
| FR2711993B1 (fr) | 1993-11-05 | 1995-12-01 | Rhone Poulenc Rorer Sa | Médicaments contenant des dérivés de 7H-imidazol[1,2-a]pyrazine-8-one, les nouveaux composés et leur préparation. |
| US6334997B1 (en) * | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| CN1087725C (zh) * | 1994-03-25 | 2002-07-17 | 同位素技术有限公司 | 用氘代方法增强药物效果 |
| FR2723373B1 (fr) | 1994-08-02 | 1996-09-13 | Rhone Poulenc Rorer Sa | Forme purifiee de streptogramines, sa preparation et les compositions pharmaceutiques qui la contiennent |
| AU5348396A (en) | 1995-05-01 | 1996-11-21 | Fujisawa Pharmaceutical Co., Ltd. | Imidazo 1,2-a pyridine and imidazo 1,2-a pyridezine derivati ves and their use as bone resorption inhibitors |
| US5593997A (en) * | 1995-05-23 | 1997-01-14 | Pfizer Inc. | 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors |
| US6249495B1 (en) | 1997-02-27 | 2001-06-19 | Matsushita Electric Industrial Co., Ltd. | Stepping motor control method and disk drive apparatus |
| SE9704404D0 (sv) | 1997-11-28 | 1997-11-28 | Astra Ab | New compounds |
| DE19948434A1 (de) | 1999-10-08 | 2001-06-07 | Gruenenthal Gmbh | Substanzbibliothek enthaltend bicyclische Imidazo-5-amine und/oder bicyclische Imidazo-3-amine |
| JP2001302667A (ja) | 2000-04-28 | 2001-10-31 | Bayer Ag | イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体 |
| AU2001275076A1 (en) | 2000-06-19 | 2002-01-02 | Armin S. Tay | Axial position changing transmission mechanism |
| GB0018473D0 (en) | 2000-07-27 | 2000-09-13 | Merck Sharp & Dohme | Therapeutic agents |
| DE10050663A1 (de) | 2000-10-13 | 2002-04-18 | Gruenenthal Gmbh | Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung |
| US20030089434A1 (en) | 2000-11-20 | 2003-05-15 | Flynn Thomas M. | Method and apparatus for the preparation and usage of a cryogenic propellant or explosive system |
| DK174233B1 (da) | 2000-12-27 | 2002-10-07 | Dss Danish Separation Systems | Sanitært spiralfilteranlæg |
| US20040102455A1 (en) | 2001-01-30 | 2004-05-27 | Burns Christopher John | Method of inhibiting kinases |
| GB0103926D0 (en) | 2001-02-17 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
| WO2002076985A1 (en) | 2001-03-23 | 2002-10-03 | Smithkline Beecham Corporation | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases |
| US7230941B2 (en) | 2001-04-26 | 2007-06-12 | Qualcomm Incorporated | Preamble channel decoding |
| FR2824092B1 (fr) | 2001-04-30 | 2004-04-09 | Camille Jim Riviere | Ensemble d'elements de construction |
| US7003125B2 (en) | 2001-09-12 | 2006-02-21 | Seung-Hwan Yi | Micromachined piezoelectric microspeaker and fabricating method thereof |
| EP1308716A1 (en) * | 2001-10-03 | 2003-05-07 | Avantium International B.V. | Method for performing a transmission diffraction analysis |
| JP2005523288A (ja) | 2002-02-19 | 2005-08-04 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | 疾病治療用の縮合した二環式−ｎ−架橋−複素環式芳香族カルボキサミド |
| CA2482991A1 (en) * | 2002-04-19 | 2003-10-30 | Cellular Genomics, Inc. | Imidazo[1,2-a]pyrazin-8-ylamines method of making and method of use thereof |
| US20040072081A1 (en) | 2002-05-14 | 2004-04-15 | Coleman Thomas P. | Methods for etching photolithographic reticles |
| JP2004053714A (ja) | 2002-07-17 | 2004-02-19 | Fuji Xerox Co Ltd | 画像定着装置及び画像定着方法 |
| US20040026867A1 (en) | 2002-08-09 | 2004-02-12 | Adams David J. | Bearing seal |
| US6761361B2 (en) | 2002-08-09 | 2004-07-13 | Credo Technology Corporation | Drill and drive apparatus with improved tool holder |
| US7312341B2 (en) * | 2002-09-09 | 2007-12-25 | Cgi Pharmaceuticals, Inc. | 6-aryl-imidazo[1,2-a] pyrazin-8-ylamines, method of making, and method of use thereof |
| ATE378336T1 (de) | 2002-09-19 | 2007-11-15 | Schering Corp | Imidazopyridine als hemmstoffe cyclin abhängiger kinasen |
| US7186740B2 (en) * | 2002-09-23 | 2007-03-06 | Schering Corporation | Imidazopyrazines as cyclin dependent kinase inhibitors |
| TW200413378A (en) | 2002-09-23 | 2004-08-01 | Schering Corp | Novel imidazopyrazines as cyclin dependent kinase inhibitors |
| JP4056346B2 (ja) | 2002-09-30 | 2008-03-05 | 三洋電機株式会社 | 非水電解質二次電池 |
| EP1581236B1 (en) | 2002-10-29 | 2013-10-16 | Insmed Incorporated | Sustained release of antiinfectives |
| WO2004072081A1 (en) | 2003-02-10 | 2004-08-26 | Cellular Genomics, Inc. | Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of kinase activity |
| AR043002A1 (es) | 2003-02-18 | 2005-07-13 | Altana Pharma Ag | Imidazopirazinas 6-substituidos |
| US7186832B2 (en) | 2003-02-20 | 2007-03-06 | Sugen Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors |
| US7157460B2 (en) * | 2003-02-20 | 2007-01-02 | Sugen Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors |
| US7456393B2 (en) | 2003-04-10 | 2008-11-25 | Ge Homeland Protection, Inc. | Device for testing surfaces of articles for traces of explosives and/or drugs |
| US20060183746A1 (en) * | 2003-06-04 | 2006-08-17 | Currie Kevin S | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds |
| US7405295B2 (en) * | 2003-06-04 | 2008-07-29 | Cgi Pharmaceuticals, Inc. | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds |
| US7393848B2 (en) | 2003-06-30 | 2008-07-01 | Cgi Pharmaceuticals, Inc. | Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds |
| US20050009632A1 (en) * | 2003-07-08 | 2005-01-13 | Karsten Manufacturing Corporation | Iron type golf club head with low profile tuning port |
| US7259164B2 (en) * | 2003-08-11 | 2007-08-21 | Cgi Pharmaceuticals, Inc. | Certain substituted imidazo[1,2-a]pyrazines, as modulators of kinase activity |
| US7144907B2 (en) | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
| US7236749B2 (en) | 2003-10-15 | 2007-06-26 | Honeywell International Inc. | Stuck microphone deselection system and method |
| US20050288295A1 (en) * | 2003-11-11 | 2005-12-29 | Currie Kevin S | Certain imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof |
| WO2005085252A1 (en) | 2004-03-04 | 2005-09-15 | Biofocus Discovery Limited | Imidazo ‘1,2-a’ pyrazine compounds which interact with protein kinases |
| JP2006099930A (ja) | 2004-09-01 | 2006-04-13 | Tdk Corp | 情報記録媒体、記録再生装置およびスタンパー |
| US8145601B2 (en) | 2004-09-09 | 2012-03-27 | Microsoft Corporation | Method, system, and apparatus for providing resilient data transfer in a data protection system |
| ATE479687T1 (de) * | 2004-10-15 | 2010-09-15 | Takeda Pharmaceutical | Kinaseinhibitoren |
| CA2587192A1 (en) | 2004-11-10 | 2006-05-18 | Cgi Pharmaceuticals, Inc. | Imidazo[1 , 2-a] pyrazin-8-ylamines useful as modulators of kinase activity |
| CN101124227A (zh) | 2004-11-10 | 2008-02-13 | Cgi制药有限公司 | 可用作激酶活性调节剂的咪唑并[1,2-a]吡嗪-8-基胺 |
| WO2007008541A2 (en) | 2005-07-08 | 2007-01-18 | Kalypsys, Inc. | Cellular cholesterol absorption modifiers |
| JP4883959B2 (ja) | 2005-08-17 | 2012-02-22 | Ｎｔｎ株式会社 | 回転検出装置および回転検出装置付き軸受 |
| GB0520838D0 (en) * | 2005-10-13 | 2005-11-23 | Glaxo Group Ltd | Novel compounds |
| EP1945216A1 (en) | 2005-11-10 | 2008-07-23 | Schering Corporation | Methods for inhibiting protein kinases |
| TW200804386A (en) * | 2005-11-10 | 2008-01-16 | Schering Corp | Imidazopyrazines as protein kinase inhibitors |
| JP4837378B2 (ja) | 2006-01-04 | 2011-12-14 | 株式会社日立製作所 | データの改竄を防止する記憶装置 |
| US7446352B2 (en) | 2006-03-09 | 2008-11-04 | Tela Innovations, Inc. | Dynamic array architecture |
| DE102006032495A1 (de) | 2006-07-13 | 2008-02-07 | Nokia Siemens Networks Gmbh & Co.Kg | Verfahren und Vorrichtung zur Vermeidung von Interferenzen in einem zellulären Funkkommunikationssystem |
| US20080025821A1 (en) | 2006-07-25 | 2008-01-31 | Applied Materials, Inc. | Octagon transfer chamber |
| JP5336375B2 (ja) | 2006-08-30 | 2013-11-06 | セルゾーム リミテッド | キナーゼ阻害剤としてのトリアゾール誘導体 |
| ES2307402B1 (es) | 2006-10-30 | 2009-09-30 | Archivel Farma, S.L. | Vacuna profilactica contra la tuberculosis. |
| JP2010511019A (ja) | 2006-12-01 | 2010-04-08 | ガラパゴス・ナムローゼ・フェンノートシャップ | 変性疾患及び炎症性疾患の治療に有用なイミダゾロピリジン化合物 |
| US7657023B2 (en) | 2007-06-08 | 2010-02-02 | At&T Intellectual Property I, L.P. | Splitter wall plates for digital subscriber line (DSL) communication systems and methods to use the same |
| CA2708361C (en) | 2007-12-14 | 2016-06-07 | F. Hoffmann-La Roche Ag | Novel imidazo[1,2-a]pyridine and imidazo[1,2-b]pyridazine derivatives |
| JP5496915B2 (ja) * | 2008-02-13 | 2014-05-21 | シージーアイ ファーマシューティカルズ，インコーポレーテッド | ６−アリール−イミダゾ［１，２−ａ］ピラジン誘導体、その製造方法、及びその使用方法 |
| US8338604B2 (en) | 2008-06-20 | 2012-12-25 | Bristol-Myers Squibb Company | Imidazopyridine and imidazopyrazine compounds useful as kinase inhibitors |
| CA2726460C (en) | 2008-07-15 | 2017-02-21 | F. Hoffmann-La Roche Ag | Novel phenyl-imidazopyridines and pyridazines |
| WO2010006970A1 (en) * | 2008-07-18 | 2010-01-21 | F. Hoffmann-La Roche Ag | Novel phenylimidazopyrazines |
| TWI453207B (zh) | 2008-09-08 | 2014-09-21 | Signal Pharm Llc | 胺基三唑并吡啶，其組合物及使用其之治療方法 |
| US8450321B2 (en) * | 2008-12-08 | 2013-05-28 | Gilead Connecticut, Inc. | 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor |
| EA021293B1 (ru) | 2008-12-08 | 2015-05-29 | Джилид Коннектикут, Инк. | ИМИДАЗОПИРАЗИНОВЫЕ ИНГИБИТОРЫ Syk, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ИМИДАЗОПИРАЗИНОВЫЕ ИНГИБИТОРЫ Syk, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| CN102307474B (zh) | 2008-12-08 | 2015-04-01 | 吉利德康涅狄格股份有限公司 | 咪唑并吡嗪syk抑制剂 |
| US20110099133A1 (en) | 2009-10-28 | 2011-04-28 | Industrial Technology Research Institute | Systems and methods for capturing and managing collective social intelligence information |
| CN103168039B (zh) | 2010-03-11 | 2016-08-03 | 吉利德康涅狄格公司 | 咪唑并吡啶类syk抑制剂 |
| US20140148430A1 (en) | 2012-11-26 | 2014-05-29 | Gilead Connecticut, Inc. | Imidazopyridines syk inhibitors |
| EA029281B1 (ru) | 2013-07-30 | 2018-03-30 | Джилид Коннектикут, Инк. | Полиморф ингибиторов syk |
| CA2919522C (en) | 2013-07-30 | 2019-02-26 | Gilead Connecticut, Inc. | Formulation of syk inhibitors |
| NZ715747A (en) | 2013-07-31 | 2017-03-31 | Gilead Sciences Inc | Syk inhibitors |
| CN105764516A (zh) | 2013-12-04 | 2016-07-13 | 吉利德科学公司 | 治疗癌症的方法 |
| TWI662037B (zh) | 2013-12-23 | 2019-06-11 | 美商基利科學股份有限公司 | 脾酪胺酸激酶抑制劑 |
| US9290505B2 (en) | 2013-12-23 | 2016-03-22 | Gilead Sciences, Inc. | Substituted imidazo[1,2-a]pyrazines as Syk inhibitors |
| BR112016028641A2 (pt) | 2014-07-14 | 2017-08-22 | Gilead Sciences Inc | ?método para tratar câncer? |
| TW201617074A (zh) | 2014-07-14 | 2016-05-16 | 吉李德科學股份有限公司 | Ｓｙｋ（脾酪胺酸激酶）抑制劑 |
| TW201639573A (zh) | 2015-02-03 | 2016-11-16 | 吉李德科學股份有限公司 | 有關治療癌症之合併治療 |
| CN107530354A (zh) | 2015-04-21 | 2018-01-02 | 吉利德科学公司 | 使用syk抑制剂对慢性移植物抗宿主病的治疗 |
| ES2674236T3 (es) | 2015-07-07 | 2018-06-28 | Swiss Coffee Innovation Ag | Cápsula que contiene bebida en polvo instantánea, en especial para la preparación de café hervido |
| US10111882B2 (en) | 2016-09-14 | 2018-10-30 | Gilead Sciences, Inc. | SYK inhibitors |
| TW201822764A (zh) | 2016-09-14 | 2018-07-01 | 美商基利科學股份有限公司 | Syk抑制劑 |
-
2009
- 2009-12-07 EA EA201190043A patent/EA021293B1/ru not_active IP Right Cessation
- 2009-12-07 SG SG2011041266A patent/SG171993A1/en unknown
- 2009-12-07 WO PCT/US2009/006446 patent/WO2010068258A1/en not_active Ceased
- 2009-12-07 AU AU2009325133A patent/AU2009325133B2/en not_active Ceased
- 2009-12-07 CA CA2745871A patent/CA2745871C/en not_active Expired - Fee Related
- 2009-12-07 CN CN201410228824.4A patent/CN104059073B/zh not_active Expired - Fee Related
- 2009-12-07 US US12/632,151 patent/US8440667B2/en not_active Expired - Fee Related
- 2009-12-07 EP EP09832229.0A patent/EP2373318B1/en active Active
- 2009-12-07 MX MX2011006094A patent/MX2011006094A/es active IP Right Grant
- 2009-12-07 KR KR1020117015710A patent/KR101743784B1/ko not_active Expired - Fee Related
- 2009-12-07 ES ES09832229T patent/ES2744541T3/es active Active
- 2009-12-07 PE PE2011001185A patent/PE20120121A1/es not_active Application Discontinuation
- 2009-12-07 SG SG10201707798SA patent/SG10201707798SA/en unknown
- 2009-12-07 CN CN200980156329.4A patent/CN102307581B/zh not_active Expired - Fee Related
- 2009-12-07 BR BRPI0922226A patent/BRPI0922226A2/pt not_active IP Right Cessation
- 2009-12-07 NZ NZ593460A patent/NZ593460A/xx not_active IP Right Cessation
- 2009-12-07 EP EP19177110.4A patent/EP3552607A3/en not_active Withdrawn
- 2009-12-07 JP JP2011539525A patent/JP5696052B2/ja not_active Expired - Fee Related
-
2011
- 2011-06-06 IL IL213405A patent/IL213405A0/en not_active IP Right Cessation
- 2011-06-07 CL CL2011001361A patent/CL2011001361A1/es unknown
- 2011-06-21 CO CO11077859A patent/CO6390109A2/es active IP Right Grant
-
2013
- 2013-04-12 US US13/862,194 patent/US8962835B2/en active Active
- 2013-04-12 US US13/862,147 patent/US8796270B2/en active Active
-
2014
- 2014-05-22 JP JP2014105805A patent/JP2014148546A/ja not_active Withdrawn
-
2015
- 2015-02-23 US US14/629,390 patent/US9567348B2/en not_active Expired - Fee Related
- 2015-12-06 IL IL242955A patent/IL242955A/en not_active IP Right Cessation
-
2016
- 2016-05-02 AU AU2016202807A patent/AU2016202807B2/en not_active Ceased
-
2017
- 2017-01-11 US US15/404,120 patent/US10093684B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012510998A5 (https=) | ||
| JP2013522238A5 (https=) | ||
| JP7421507B2 (ja) | ハンチントン病を処置するためのヘテロ環式およびヘテロアリール化合物 | |
| US20220305014A1 (en) | Inhibitors of cyclin dependent kinase 7 (cdk7) | |
| JP7649257B2 (ja) | ハンチントン病を処置するための化合物 | |
| AU2016219585B2 (en) | Imidazopyridines Syk inhibitors | |
| JP6517976B2 (ja) | 炎症性障害の治療のための化合物及びその医薬組成物 | |
| CN105339370B (zh) | 用于治疗炎症性疾病的化合物和及其药物组合物 | |
| CA2863874C (en) | Compounds for treating spinal muscular atrophy | |
| CA2746023C (en) | Imidazopyrazine syk inhibitors | |
| KR102057351B1 (ko) | 척수성 근위축증을 치료하기 위한 화합물 | |
| TWI482774B (zh) | 作爲ＬＲＲＫ２抑制劑之新穎４－（經取代胺基）－７Ｈ－吡咯并［２，３－ｄ］嘧啶類 | |
| CA2959501C (en) | Probes for imaging huntingtin protein | |
| AU2009325133B2 (en) | Imidazopyrazine Syk inhibitors | |
| TWI501965B (zh) | 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物 | |
| CN104039790B (zh) | 嘌呤衍生物及它们在治疗疾病中的应用 | |
| CA2775475C (en) | Pyridinylimidazolone derivatives for the inhibition of pi3 kinases | |
| KR101803984B1 (ko) | Ｐｄｅ１０ａ 효소 저해제로서의 헤테로방향족 페닐이미다졸 유도체 | |
| KR101779629B1 (ko) | Ｐｄｅ10ａ 효소 저해제로서의 헤테로방향족 아릴 트리아졸 유도체 | |
| KR20150002573A (ko) | 벤조티아졸-6-일 아세트산 유도체 및 ｈｉｖ 감염을 치료하기 위한 이의 용도 | |
| JP2016507551A5 (https=) | ||
| KR20170083134A (ko) | 시르투인 조정제로서의 치환된 가교된 우레아 유사체 | |
| IL293191A (en) | Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use | |
| US20240132509A1 (en) | Heterocyclic and heteroaryl compounds for treating huntington's disease |